PMID- 33609664
OWN - NLM
STAT- MEDLINE
DCOM- 20220304
LR  - 20220304
IS  - 1096-3650 (Electronic)
IS  - 1044-579X (Linking)
VI  - 74
DP  - 2021 Sep
TI  - Extracellular Vesicle (EV) biohybrid systems for cancer therapy: Recent advances 
      and future perspectives.
PG  - 45-61
LID - S1044-579X(21)00029-8 [pii]
LID - 10.1016/j.semcancer.2021.02.006 [doi]
AB  - Extracellular vesicles (EVs) are a class of cell-derived lipid-bilayer membrane 
      vesicles secreted by almost all mammalian cells and involved in intercellular 
      communication by shuttling various biological cargoes. Over the last decade, EVs 
      - namely exosomes and microvesicles - have been extensively explored as 
      next-generation nanoscale drug delivery systems (DDSs). This is in large due to 
      their endogenous origin, which enables EVs to circumvent some of the limitations 
      associated with existing cancer therapy approaches (i.e. by preventing 
      recognition by the immune system and improving selectivity towards tumor tissue). 
      However, successful translation of these cell-derived vesicles into clinical 
      applications has been hindered by several factors, among which the loading of 
      exogenous therapeutic molecules still represents a great challenge. In order to 
      address this issue and to further advance these biologically-derived systems as 
      drug carriers, EV-biohybrid nano-DDSs, obtained through the fusion of EVs with 
      conventional synthetic nano-DDSs, have recently been proposed as a valuable 
      alternative as DDSs. Building on the idea of "combining the best of both worlds", 
      a combination of these two unique entities aims to harness the beneficial 
      properties associated with both EVs and conventional nano-DDSs, while overcoming 
      the flaws of the individual components. These biohybrid systems also provide a 
      unique opportunity for exploitation of new synergisms, often leading to improved 
      therapeutic outcomes, thus paving the way for advancements in cancer therapy. 
      This review aims to describe the recent developments of EV-biohybrid nano-DDSs in 
      cancer therapy, to highlight the most promising results and breakthroughs, as 
      well as to provide a glimpse on the possible intrinsic targeting mechanisms of 
      EVs that can be bequeathed to their hybrid systems. Finally, we also provide some 
      insights in the future perspectives of EV-hybrid DDSs.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Ou, Yi-Hsuan
AU  - Ou YH
AD  - Department of Pharmacy, National University of Singapore, Singapore.
FAU - Liang, Jeremy
AU  - Liang J
AD  - Department of Pharmacy, National University of Singapore, Singapore.
FAU - Czarny, Bertrand
AU  - Czarny B
AD  - School of Materials Science & Engineering and Lee Kong Chian School of Medicine, 
      Nanyang Technological University, Singapore, Singapore.
FAU - Wacker, Matthias G
AU  - Wacker MG
AD  - Department of Pharmacy, National University of Singapore, Singapore.
FAU - Yu, Victor
AU  - Yu V
AD  - Department of Pharmacy, National University of Singapore, Singapore.
FAU - Wang, Jiong-Wei
AU  - Wang JW
AD  - Department of Surgery, Yong Loo Lin School of Medicine, National University of 
      Singapore, Singapore, Singapore; Cardiovascular Research Institute, National 
      University Heart Centre, Singapore, Singapore; Department of Physiology, Yong Loo 
      Lin School of Medicine, National University of Singapore, Singapore, Singapore. 
      Electronic address: surwang@nus.edu.sg.
FAU - Pastorin, Giorgia
AU  - Pastorin G
AD  - Department of Pharmacy, National University of Singapore, Singapore. Electronic 
      address: phapg@nus.edu.sg.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210217
PL  - England
TA  - Semin Cancer Biol
JT  - Seminars in cancer biology
JID - 9010218
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage
MH  - Drug Carriers/*administration & dosage
MH  - Drug Delivery Systems/*methods/*trends
MH  - *Extracellular Vesicles
MH  - Humans
MH  - Nanotechnology/methods/trends
MH  - Neoplasms/*drug therapy
OTO - NOTNLM
OT  - Extracellular vesicles
OT  - Hybrid drug delivery systems
OT  - Synthetic nanoparticles
OT  - Targeting mechanisms
EDAT- 2021/02/21 06:00
MHDA- 2022/03/05 06:00
CRDT- 2021/02/20 20:09
PHST- 2020/10/30 00:00 [received]
PHST- 2021/02/10 00:00 [revised]
PHST- 2021/02/10 00:00 [accepted]
PHST- 2021/02/21 06:00 [pubmed]
PHST- 2022/03/05 06:00 [medline]
PHST- 2021/02/20 20:09 [entrez]
AID - S1044-579X(21)00029-8 [pii]
AID - 10.1016/j.semcancer.2021.02.006 [doi]
PST - ppublish
SO  - Semin Cancer Biol. 2021 Sep;74:45-61. doi: 10.1016/j.semcancer.2021.02.006. Epub 
      2021 Feb 17.